Network analysis of brain perfusion in [11C]UCB-J PET: Parkinson’s related motor pattern (PDRP)
Objective: The aim was to investigate the use of R1 (relative delivery parameter) as a surrogate of blood perfusion to identify brain networks specific to…The Healthy Brain Ageing (HeBA) Parkinson’s disease risk survey: Study design and methods
Objective: To present Healthy Brain Ageing (HeBA) – a European multi-centre population-based study on the prevalence and predictivity of risk factors for Parkinson´s Disease. Background:…Results from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease
Objective: The objective of the Phase 2b-trial was to investigate efficacy and safety of three doses of Mesdopetam as adjunct treatment in patients with PD…Apathy correlated with motor and non-symptoms in de-novo patients with Parkinson’s disease
Objective: We aimed to investigate how the severity of apathy affects motor symptom and other non-motor symptoms in patients with de-novo Parkinson’s disease (PD). Background:…Repurposing the MDS-UPDRS part III for early-stage Parkinson’s disease: Supportive evidence for a bradykinesia and rigidity specific sub-score
Objective: Characterize specific motor signs and their impact on the daily life of people with early-stage Parkinson’s disease (PD) before initiation of symptomatic treatment (ST)…PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…Assessing the optimal pallidal target in deep brain stimulation for Parkinson’s disease: A single-center retrospective review
Objective: To characterize globus pallidus internus (GPi) deep brain stimulation (DBS) active contact location at one-year post-op for Parkinson’s disease (PD) patients at our center.…Effectiveness of use of Pictographs on Levodopa packaging to ensure awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease.
Objective: Food interferes with gastrointestinal absorption of levodopa which requires spacing with meals. This study aimed to evaluate the effect pictographs on Levodopa packaging Fig 1 on increasing patient…Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…Risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
Objective: The present meta-analysis aims to find out association between risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia (LID) patients with Parkinson’s disease (PD).…
- « Previous Page
- 1
- …
- 371
- 372
- 373
- 374
- 375
- …
- 553
- Next Page »